Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study.
Drugs R D
; 22(3): 245-252, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-2031052
ABSTRACT
BACKGROUND:
The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been defined in clinical trials, but no real-world data are currently available. We aimed to assess the safety and effectiveness of upadacitinib in a real-world AD patient cohort that mostly included patients who failed the available systemic therapies, including dupilumab.METHODS:
Prospective cohort study collecting data on upadacitinib-treated AD adult patients completing at least 16 weeks of therapy.RESULTS:
Forty-three patients showed rapid and marked response to upadacitinib with significant reduction of all disease severity scores since the first follow-up visit. At week 16, Eczema Area and Severity Index (EASI) 75, EASI 90, and EASI 100 response was observed in 97.5%, 82.1%, and 69.2% of patients, respectively. EASI 90 response reflected the achievement of a clear or almost clear condition (POEM 0-2), self-evaluated by 79.5% of patients. Patients' quality of life improved as suggested by the achievement of DLQI 0/1 by 38.5% of patients at week 4, and by 76.9% at week 16.CONCLUSION:
Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients unresponsive to dupilumab, who were not included in upadacitinib trials.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dermatitis, Atopic
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
Language:
English
Journal:
Drugs R D
Journal subject:
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
S40268-022-00396-1
Similar
MEDLINE
...
LILACS
LIS